Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 26 04:00PM ET
18.68
Dollar change
+0.40
Percentage change
2.19
%
IndexRUT P/E- EPS (ttm)- Insider Own34.64% Shs Outstand41.21M Perf Week-2.66%
Market Cap735.24M Forward P/E- EPS next Y-4.84 Insider Trans24.31% Shs Float25.73M Perf Month-16.64%
Income- PEG- EPS next Q-1.05 Inst Own66.57% Short Float13.21% Perf Quarter-18.21%
Sales- P/S- EPS this Y66.73% Inst Trans- Short Ratio10.91 Perf Half Y-
Book/sh9.84 P/B1.90 EPS next Y11.91% ROA- Short Interest3.40M Perf Year-
Cash/sh10.31 P/C1.81 EPS next 5Y- ROE- 52W Range13.14 - 33.92 Perf YTD-19.31%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-44.93% Beta-
Dividend TTM- Quick Ratio19.35 Sales past 5Y0.00% Gross Margin- 52W Low42.16% ATR (14)1.50
Dividend Ex-Date- Current Ratio19.35 EPS Y/Y TTM- Oper. Margin- RSI (14)34.21 Volatility4.22% 6.12%
Employees- Debt/Eq0.07 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price31.00
Option/ShortNo / Yes LT Debt/Eq0.06 EPS Q/Q- Payout- Rel Volume0.29 Prev Close18.28
Sales Surprise- EPS Surprise8.10% Sales Q/Q- EarningsMar 21 AMC Avg Volume311.57K Price18.68
SMA20-8.20% SMA50-20.97% SMA200-11.73% Trades Volume89,542 Change2.19%
Date Action Analyst Rating Change Price Target Change
Dec-05-23Initiated Truist Buy $34
Dec-05-23Initiated TD Cowen Outperform
Dec-05-23Initiated JP Morgan Overweight $23
Dec-05-23Initiated Jefferies Buy $28
Cargo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cell therapies for cancer patients. It is involved in evaluating its lead program, CRG-022, an autologous CD22 chimeric antigen receptor T-cell therapy candidate, in a potentially pivotal Phase 2 clinical trial in patients with large B-cell lymphoma whose disease relapsed or was refractory to CD19 CAR T-cell therapy. The company was founded by Crystal Mackall, Nancy Goodman, Louai Labanieh, and Robbie Majzner in December 2019 and is headquartered in San Mateo, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Third Rock Ventures V, L.P.10% OwnerNov 14 '23Buy15.001,333,33319,999,9951,807,119Nov 14 07:08 PM
PERCEPTIVE ADVISORS LLCFormer 10% OwnerNov 14 '23Buy15.00666,6669,999,9902,912,835Nov 14 04:32 PM
Samsara BioCapital GP, LLC10% OwnerNov 14 '23Buy15.00666,6669,999,9904,121,689Nov 16 07:39 PM